TaiMed Biologics

4147.TWO

1.68 USD

-0.03

-1.75%

Overview

Last close

1.68 usd

Market cap

460.25M usd

52 week high

3.24 usd

52 week low

1.60 usd

Target price

6.05 usd

Valuation

P/E

N/A

Forward P/E

1111.1111

Price/Sales

24.2059

Price/Book Value

3.6223

Enterprise Value

407.43M usd

EV/Revenue

21.3102

EV/EBITDA

543.5886

Key financials

Revenue TTM

19.12M usd

Gross Profit TTM

7.11M usd

EBITDA TTM

-2.76M usd

Earnings per Share

-0.03 usd

Dividend

N/A usd

Total assets

158.10M usd

Net debt

N/A usd

About

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.